AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 191 min read$DRTS

Alpha Tau Medical Ltd. (DRTS) Wins FDA OK to Expand REGAIN Trial to 20 Patients

Alpha Tau Medical Ltd. (DRTS) received FDA approval to expand its REGAIN trial for recurrent glioblastoma from 10 to 20 patients, adding secondary endpoints and an interim analysis. The company plans to present new data at SNO 2026.

Original reporting
tradingview.com
Published Oct 19, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 12:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Alpha Tau Medical Ltd. (DRTS) Wins FDA OK to Expand REGAIN Trial to 20 Patients — source image
Source · tradingview.com
Decision brief

The 30-second read

$DRTSBullishMed
01

Why it matters

Regulatory clearance is a key milestone for early-stage biotech companies, potentially lifting the stock as investors anticipate stronger data.

02

Market read

The FDA approval is a primary catalyst for Alpha Tau Medical, likely influencing its share price in the short term.

03

What to watch

The FDA supplement adds secondary endpoints, which may increase trial complexity and risk.

Relevance 8/10Novelty 8/10Timing: today

Background

Alpha Tau Medical announced FDA approval to expand its REGAIN recurrent glioblastoma trial from 10 to up to 20 patients, adding secondary endpoints and an interim analysis.

Company-level read

Ticker impact

$DRTSBullishHigh confidence
Context

FDA approved an IDE supplement expanding Alpha Tau Medical's REGAIN trial to up to 20 patients.

Expected impact

potential upside as investors price in expanded trial scope

Evidence & confidence

Regulatory approval is a material catalyst for a biotech; the added patients increase data robustness.

Market effects

Sector

May boost sentiment for early-stage glioblastoma therapeutics and related biotech peers.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minor global impact, confined to niche oncology research community.

Counterpoint

What could challenge this read

Trial expansion could delay later-stage data, extending cash burn without immediate revenue.

Key entities

  • Company
    Alpha Tau Medical Ltd.

    Biotech firm developing therapies for glioblastoma.

  • Regulator
    FDA

    U.S. Food and Drug Administration granting trial expansion approval.

Read at source← All news

StoryFDA approves expansion of Alpha Tau’s REGAIN glioblastoma trial to 20 patients

Also covered by

1 outlet

Related articles

OCT 19
$DRTSHighAI 9/10

FDA Greenlights Expansion of Alpha Tau’s Brain Cancer Trial, With New Data Weeks Away (NASDAQ: DRTS) By FinanceWire

Alpha Tau Medical (NASDAQ: DRTS) received FDA approval to expand its U.S. brain cancer trial, doubling enrollment to 20 patients. The company will present updated REGAIN trial data on November 13, including new measures like progression-free survival and quality of life. Alpha DaRT technology aims to treat recurrent glioblastoma with localized radiation.

investing.com2 min
OCT 19
$DRTSMedAI 8/10

FDA expands Alpha Tau glioblastoma trial to 20 patients

Alpha Tau Medical (NASDAQ:DRTS) received FDA approval to expand its REGAIN trial for recurrent glioblastoma, increasing enrollment to 20 patients and adding new endpoints. The trial, presented at the Society for Neuro-Oncology Annual Meeting, evaluates the safety and feasibility of Alpha DaRT therapy. Alpha Tau's treatment is not yet approved for commercial use.

investing.com2 min
SEP 15
$DRTSHighAI 9/10

Alpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next.

Alpha Tau Medical (NASDAQ: DRTS) reported strong results from cancer trials, including a 100% response rate in head and neck cancer and promising data in brain and pancreatic cancers. The company expects key data readouts in late 2026 and early 2027, which could impact its trajectory. Alpha Tau has $104.8 million in cash and a U.S. commercialization partnership with Tolmar.

investegate.co.uk3 min
JUL 21
$DRTSMedAI 8/10

Alpha Tau Shows 100% ORR With Alpha DaRT Plus Keytruda In Head And Neck Squamous Cell Carcinoma

Alpha Tau Medical (DRTS) reported positive early clinical results for Alpha DaRT plus pembrolizumab (Keytruda) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma. In nine evaluable patients, the company said ORR was 100% with 44% complete responses and median overall survival of 18.2 months. DRTS shares closed at $13.47.

rttnews.com4 min
JUL 15
$DRTSMed

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.

manilatimes.net4 min